Welcome to our dedicated page for Rapid Theraptic Scince Lab news (Ticker: RTSL), a resource for investors and traders seeking the latest updates and insights on Rapid Theraptic Scince Lab stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rapid Theraptic Scince Lab's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rapid Theraptic Scince Lab's position in the market.
Rapid Therapeutics Science Laboratories (OTC: RTSL) has postponed its shareholder update conference call originally scheduled for today. The company will announce a new date for the call soon. RTSL specializes in the manufacturing of aerosol delivery systems for non-psychoactive cannabinoid compounds, including Cannabidiol (CBD). Their nhāler product line adheres to good manufacturing practices. It’s noteworthy that CBD products are not FDA-approved. RTSL emphasizes that its products are not intended for therapeutic claims or disease prevention.
Rapid Therapeutics Science Laboratories (OTC: RTSL) is set to present a corporate overview at the 14th Annual LD Micro Main Event Conference in Los Angeles from October 12-14, 2021. CEO Donal Schmidt will speak on October 12 at 12:00 PM PT / 3:00 PM ET. The company specializes in aerosol manufacturing of non-psychoactive cannabinoid compounds and is preparing to file an IND application with the FDA for its CBD metered dose inhaler. RTSL's products, containing zero THC, are not FDA-approved for human consumption.
Rapid Therapeutics Science Laboratories (OTC: RTSL) announces a shareholder update conference call scheduled for October 7, 2021, at 4:30 PM ET, led by CEO Donal Schmidt. Interested participants can join by dialing 1-866-652-5200 (domestic) or 1-412-317-6060 (international), approximately 10 minutes before the start time. A live webcast will also be available, with a replay accessible until December 7, 2021. RTSL specializes in aerosol manufacturing focused on non-psychoactive cannabinoid delivery, having developed a proprietary formulation for pressurized metered dose inhalers (pMDI) in compliance with GMP.
Rapid Therapeutic Science Laboratories (RTSL) has entered into an agreement to sell a $1.9 million convertible promissory note and associated warrants to an institutional investor, anticipated to yield approximately $1.7 million in gross proceeds. The deal is facilitated by Maxim Group LLC as the placement agent. The securities will not be registered under the Securities Act of 1933 and are subject to customary closing conditions. RTSL focuses on aerosol manufacturing of non-psychoactive cannabinoid compounds through its nhāler product line.
Rapid Therapeutic Science Laboratories (RTSL) has concluded lab development on three proprietary pharmaceutical formulas for cannabinoid isolates, specifically targeting metered dose inhalers (MDI). The company developed two CBD formulas and one CBG formula, with plans to submit an Investigational New Drug Application to the FDA. CEO Donal R. Schmidt, Jr. emphasized the need for a unique manufacturing process for ultra-pure isolates, which they have engineered internally. RTSL aims for GMP certification and believes their isolate production methodology could lead to patent filings soon.
Rapid Therapeutic Science Laboratories (OTC Pink: RTSL) announced the upcoming launch of its upgraded sublingual spray line, made with proprietary pharmaceutical-grade isolates. The products will be manufactured in compliance with Good Manufacturing Practice (GMP) standards at their ISO Level 6 lab. Although the company is withdrawing its metered dose inhaler (MDI) from the market to file an IND application for CBD, it continues to develop sublingual, nasal, and topical spray products. CEO Donal R. Schmidt, Jr. anticipates significant demand due to their unique formulation.
Rapid Therapeutic Science Laboratories (OTC Pink: RTSL) has announced the execution of two contracts to begin Phase 1 human clinical trials for its metered dose inhaler (MDI) featuring Cannabidiol (CBD). This move is part of their strategy to file an Investigational New Drug (IND) application with the FDA within 30 days. The studies will focus on CBD's therapeutic effects on depression, anxiety, insomnia, ADHD, and chronic pain, with oversight by Dr. Charles Powell. RTSL aims to pioneer an FDA-approved MDI containing pharmaceutical-grade CBD isolate.